Correction to: Nature Biomedical Engineering https://doi.org/10.1038/s41551-019-0431-2, published online 22 July 2019.
In the version of this Article originally published, in the heading for Fig. 1g ‘DNA-targeting CRISPR effectors (285)’, ‘285’ should have read ‘284’. In Fig. 3b,c,e and f, the final x axis label, ‘AAV5-SaCas9’ in blue, for the first dose was incorrect; the correct label is ‘AAV5-SpCas9’. These figures have now been corrected. In addition, the caption for Supplementary Fig. 2 stated that 89 Cas13a, b and c orthologs were used; the correct number is 84. In Supplementary Table 1 the Cpf1 and Cas13 sequences were missing. The Supplementary Information and Supplementary Table files have now been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moreno, A.M., Palmer, N., Alemán, F. et al. Author Correction: Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy. Nat Biomed Eng 3, 842 (2019). https://doi.org/10.1038/s41551-019-0456-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-019-0456-6
This article is cited by
-
Robust genome and cell engineering via in vitro and in situ circularized RNAs
Nature Biomedical Engineering (2024)
-
Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models
Nature Communications (2021)